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Poly(L-lactide) (PLLA) is the structural material of the first clinically
approved bioresorbable vascular scaffold (BVS), a promising alter-
native to permanent metal stents for treatment of coronary heart
disease. BVSs are transient implants that support the occluded
artery for 6 mo and are completely resorbed in 2 y. Clinical trials
of BVSs report restoration of arterial vasomotion and elimination
of serious complications such as late stent thrombosis. It is remark-
able that a scaffold made from PLLA, known as a brittle polymer,
does not fracture when crimped onto a balloon catheter or during
deployment in the artery. We used X-raymicrodiffraction to discover
how PLLA acquired ductile character and found that the crimping
process creates localized regions of extreme anisotropy; PLLA chains
in the scaffold change orientation from the hoop direction to the
radial direction on micrometer-scale distances. This multiplicity of
morphologies in the crimped scaffold works in tandem to enable a
low-stress response during deployment, which avoids fracture of
the PLLA hoops and leaves them with the strength needed to sup-
port the artery. Thus, the transformations of the semicrystalline
PLLA microstructure during crimping explain the unexpected
strength and ductility of the current BVS and point the way to thin-
ner resorbable scaffolds in the future.
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Cardiovascular disease (CVD) claims over 15 million lives peryear—more lives than communicable, maternal, neonatal,
and nutritional disorders combined and more than twice the
number of deaths due to all cancers (1). Coronary heart disease
(CHD), the narrowing of coronary arteries due to the deposition
of plaque, accounts for nearly 50% of all CVD deaths (1). To
restore blood flow, most patients receive minimally invasive bal-
loon angioplasty followed by stent implantation (1 million in 2008
in the United States) (2). Stents are metal mesh tubes that are
delivered to the target lesion while they are crimped onto a bal-
loon. Once they are positioned at the lesion, inflation of the
balloon compresses the plaque against the vessel wall and deploys
the stent to provide support at the enlarged diameter after the
balloon is deflated and withdrawn. Metal stents are permanent,
and their stiffness prohibits vasomotion and dilation (3, 4). Fur-
ther, they present a lifelong risk of late stent thrombosis (3–6). A
new technology is poised to displace metal stents: bioresorbable
vascular scaffolds (BVS), which have been deemed the “fourth
revolution” in percutaneous coronary intervention (7, 8).
The goal of tissue scaffolds is to restore the healthy state of the
tissue, rather than merely ameliorating the diseased state (9–11).
Poly(L-lactide) (PLLA) was selected as the material for BVS be-
cause its semicrystalline structure gives it adequate radial strength
[>300 mm Hg (12)], and it degrades into products that are me-
tabolized by the human body (13–16). Clinically, bioresorption of
PLLA vascular scaffolds occurs within 2–3 y, and the treated seg-
ment of the coronary artery is restored in terms of vasomotion and
vasoresponse (17–19). Success of a BVS depends on its ability to
withstand deformation during both crimping onto the balloon
and deployment at the lesion and still have sufficient strength to
hold the artery open for 6 mo or more. Achieving this with PLLA
is remarkable in view of the literature, which describes PLLA as
a brittle material with a fracture strain ranging from 5 to 13% at
temperatures below 30 °C (20–22). Scaffold deployment in the
arteries occurs in aqueous media, for which the scant literature
reports a strain at break of PLLA less than 10% (23). The usual
approaches to overcoming the tendency of PLLA to fracture,
blending (24, 25) and copolymerization (26–28), are not accept-
able for BVSs because they reduce the lifetime of the polymer in
the body (28, 29). Therefore, the material (pure PLLA) at the heart
of the first clinically approved vascular scaffold [European Confor-
mity (CE Mark) in 2011 (4) and US Food and Drug Administration
(FDA) approval in July 2016 (30)] is notorious for being brittle.
The processes for production and implantation for both stents
and scaffolds appear superficially similar: tube formation, laser-
cutting of the strut lattice, crimping, and deployment (8). However,
the strain fields and their effect on material structure and prop-
erties are dramatically different. PLLA scaffolds (∼150 μm thick)
(8) are thicker than metal stents (∼80 μm) (31) due to the lower
stiffness and mechanical strength of polymers relative to metals. As
a result, greater strains are encountered during crimping and de-
ployment of polymeric scaffolds. For example, elongation at the
outer bend (OB; Fig. 1B) of a U crest during crimping can be as
high as 50% in the θ direction (Fig. S1). This solid-state defor-
mation of the as-cut PLLA scaffold (Fig. 1A) is performed near its
glass transition (Tg ∼ 60–65 °C), where its properties depend
strongly on temperature (22) and accurate, predictive models are
not yet available. Furthermore, the effect of processing strain on
the semicrystalline microstructure of a polymer is crucial for un-
derstanding its performance, but modeling deformation-induced
morphology in semicrystalline polymers is a persistent challenge
(32). Therefore, direct observations of changes in semicrystal-
line morphology caused by deformation are needed, and the
Significance
Bioresorbable vascular scaffolds (BVSs) are poised to replace
permanent metal stents for the treatment of coronary heart
disease (CHD), which claims over 7 million lives each year. BVSs
support the artery for 6 mo but completely dissolve in 2 y,
eliminating serious long-term complications. The first clinically
approved BVS is made from a brittle material, poly (L-lactide)
(PLLA), yet it does not fracture during crimping or deployment.
We used X-ray microdiffraction to discover multiple, micron-
scale morphologies in the crimped BVS, which confer ductility
to PLLA and resist fracture upon deployment. Contrary to in-
tuition, the crimping process enhances scaffold strength, a result
that researchers should keep in mind when designing thinner
scaffolds to make BVSs broadly applicable to CHD.
Author contributions: A.A., K.R., and J.A.K. designed research; A.A. and K.R. performed
research; M.B.K., J.P.O., and J.A.K. contributed new reagents/analytic tools; A.A., K.R., and
J.A.K. analyzed data; and A.A., K.R., and J.A.K. wrote the paper.
Conflict of interest statement: M.B.K. and J.P.O. are employees of Abbott Vascular. Fund-
ing for this research was provided by Abbott Vascular.
This article is a PNAS Direct Submission.
1A.A and K.R contributed equally to this work.
2To whom correspondence should be addressed. Email: jakornfield@cheme.caltech.edu.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.
1073/pnas.1602311113/-/DCSupplemental.
11670–11675 | PNAS | October 18, 2016 | vol. 113 | no. 42 www.pnas.org/cgi/doi/10.1073/pnas.1602311113
inhomogeneous strain field imposed on the BVS during crimping
demands investigation by a technique that offers micron-scale
resolution. Recent advances in X-ray microdiffraction (33) meet
this need and provide results that reveal the basis of the balance
of ductility and strength that enables PLLA vascular scaffolds:
crimping creates a multiplicity of materials from a single one—with
strong and ductile regions arranged favorably for deployment.
Results
During the development of PLLA scaffolds, the relationship be-
tween the conditions used to produce the expanded tube, before
laser cutting, and the properties of the resulting scaffold were in-
vestigated. An extruded PLLA preform was subjected to a biaxial
elongation during tube expansion, and the relationship of hoop
elongation and axial elongation (Table S1) to mechanical proper-
ties (Fig. S2) was measured. Surprisingly, group 5 (200% hoop and
200% axial elongation; Table S1), the most ductile tube (elonga-
tion at break >25% in both the hoop and axial directions; Fig. S2 C
and D), did not perform well upon deployment [deployment di-
ameter at which fracture began was only ∼3.6 mm (Fig. S2F) and
had the largest number of fractured elements upon reaching that
diameter, >40 per scaffold; Fig. S2G]. Similarly, the expanded tube
with the second best mechanical properties (group 4, hoop elon-
gation to break ∼15% and axial elongation to break ∼45%; Fig. S2
C andD) also fractured upon deployment (∼15 cracks per scaffold;
Fig. S2G). Contrary to expectation, expanded tubes with infe-
rior mechanical properties (groups 1–3; Table S1) gave superior
structural integrity where it counts—upon deployment (fewer than
five cracks per scaffold; Fig. S2G). To our knowledge, no expla-
nation of this surprising finding has ever been offered.
To understand the success of BVS, the present study focuses on
scaffolds produced with the tube expansion conditions that are
used for current clinical BVS devices (group 3; Table S1). The
Fig. 1. SEMs of the subassemblies (as-cut, crimped,
and deployed) of a PLLA vascular scaffold. The ex-
panded tube is laser-cut to create an (A) as-cut
scaffold. (B) The U crest of an as-cut scaffold in-
dicating the IB and OB. (C) Cylindrical coordinate
system for the scaffold. (D) Crimped scaffold.
(E) A U crest of a crimped scaffold in D. (F) Deployed
scaffold. (G) Diamond-shaped voids present in a
deployed U crest.
Fig. 2. Variation in birefringence through the thickness of a crimped PLLA vascular scaffold. (A) Schematic of a U crest (Fig. 1E) indicating the OD surface, the
midplane (black dotted line), and the position of a particular section (black band). (B) Cropped polarized light micrographs of sequential 15-μm-thick microtomed
sections from the OD to the ID of a crimped U crest. Sections are labeled with C to denote “crimped” and the approximate distance in microns from the inner
diameter of the scaffold (i.e., C30 was closest to the scaffold’s ID, and C165 was closest to its OD). A bold rectangle indicates the section analyzed in Fig. 3.























resulting scaffolds afford a wide margin of safety for overdilation
without fracture (to ∼3.8 mm with few cracks, approximately five
per scaffold; Fig. S2 F andG). The apparent contradiction between
ductility of the expanded tube and the performance during de-
ployment motivates investigation of the structural changes that
occur during crimping, which reduces the diameter of the scaffold
from 3.5 mm in the as-cut form (Fig. 1A) to 1.7 mm in the crimped
state (Fig. 1D). Scanning electron micrographs (SEM) of crimped
scaffolds show that the deformation zones are localized to areas
that are ∼100 μm across (compare Fig. 1 B and E). Compression
along the θ direction (defined in Fig. 1 C and G) occurs at each
inner bend (IB; Fig. 1B) causing material to bulge out of the (θ, z)
plane (Fig. 1E). Thus, an elongation in the r direction occurs at
each inner bend, which does not occur in metal stents (Fig. S3). At
each outer bend (Fig. 1B), tension along the θ direction causes the
scaffold to thin in the r direction. Upon deployment (Fig. 1F), the
inner bend is placed under tension, but it does not fracture, despite
the brittle character associated with PLLA. Instead, a diamond-
shaped void forms (Fig. 1G) (34) in the scaffold, a feature not
observed in metal stents (Fig. S3).
Although prior data showed that the formation of diamond-
shaped voids correlates with successful deployment without
fracture (Fig. S2 G and H), no explanation of this correlation has
yet been offered. Unlike cracks, diamond-shaped voids are conical
cavities at the inner bends of U, W, and Y crests (Fig. S4A) that do
not rupture either the outer diameter (OD) or inner diameter (ID)
surface. To understand the microstructural basis of this mechanism
for yielding without failure, we use X-ray microdiffraction to gain a
3D view of the morphology created during crimping and deploy-
ment. In particular, we characterize structural transformations that
occur in U crests, which permit estimates of the strain imposed
during crimping (Fig. S1). Relative to the original 150-μm thick-
ness of the as-cut scaffold (Fig. 1A), the bulge at each inner bend
causes an increase in thickness to ∼180 μm (position + in Fig. 1E),
and the tensile deformation at the outer bend causes a decrease
in thickness to ∼110 μm (position × in Fig. 1E).
Resolution in the radial direction (r; Fig. 1C) is achieved by
microtoming sections in the (θ, z) plane (Fig. 1 A andG). Moving
from the OD to the ID of the scaffold (upper left to lower right
in Fig. 2B), we observe a steady increase in the birefringence. A
possible explanation for this trend is the gradient in both tem-
perature and strain that is set up during tube expansion (35),
before laser cutting. When hot PLLA comes into contact with a
cooler outer mold, the material close to the outer diameter is
quenched, which hinders crystallization near the OD. In addi-
tion, the tube expansion step imposes larger strains on material
at the ID (∼400%) than at the OD (∼100%). Consequently, the
material close to the ID has a greater driving force for oriented
crystallization and a longer time to crystallize before vitrification,
which may explain the observed gradient in birefringence.
A coarse-grain map of the distribution of orientation in the (θ, z)
plane, obtained using polarized light microscopy, shows craze
structures at the IB and strong orientation at the OB. In contrast
to the gradient in the r direction (from one section to the next in
Fig. 2B), gradients of birefringence in the plane of each section
must have been created by the crimping process (Fig. 1D) be-
cause the expanded tube has uniform structure in the (θ, z)
plane. The compressive forces that lead to bulge formation (Fig.
1E) cause plastic deformation and crazing at the IB (black lines
emanating from the cusp of the inner bend in Fig. 2B) (36).
Fig. 3. Structural characterization of a crimped U section (C45, bold rectangle in Fig. 2B). (A) Polarized light micrographs of C45with increasing magnification from
A, i, to provide context relative to the IB and OB, to (A, iii) a composite image (vertical dotted lines mark transitions between images) that shows positions of
microdiffraction acquisitions (marked using the X-ray beam). Squares correspond to patterns shown in B–D. Microdiffraction data acquired (B) close to the IB,
(C) midway between the IB and OB, and (D) close to the OB: (B–D, i) X-ray microdiffraction patterns, (B–D, ii) azimuthal intensity distribution I(ϕ) at the (110)/(200)
diffraction (identified in D, i, azimuthal coordinates in (B, i, averaged over q ∈ 1.08–1.24 Å−1), and (B–D, iii) radial intensity distribution I(q) (azimuthally averaged).
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Midway between the IB and the OB, there is a relatively uniform
region (orange Michel–Levy color in Fig. 2B, C45). At the outer
bend, the tensile forces in the θ direction during crimping result
in strong orientation (burnt orange Michel–Levy color in Fig. 2B,
C45). Of particular relevance to the formation of diamond-
shaped voids, section C45 contains the deepest fissures at the IB;
thus, we examine C45 using microdiffraction to probe the role of
crimping in the formation of diamond-shaped voids and en-
hancing the tensile strength of the scaffold.
Resolution in the (θ, z) plane is achieved by translating the
sample relative to the microdiffraction beam [beamline 2-ID-D of
the Advanced Photon Source (APS), Argonne National Labora-
tory, 200-nm-diameter irradiated area], typically using 5-μm steps.
The line of measurement points highlighted in Fig. 3A, iii, spans
from the compression region at the IB to the tensile region at the
OB. At the IB we observe striking, highly asymmetric diffraction
patterns (Fig. 3B, i; 25–55 μm from the innermost edge) and
complex azimuthal variation of (110)/(200) intensity (Fig. 3B, ii).
We believe this is a result of the yielding that occurs under severe
compression. Moving away from the IB (70–100 μm), the middle
zone is characterized by progressively stronger orientation (Fig.
3C, i). Moving to the OB, the crystallites have their c axis strongly
aligned parallel to the θ direction (Fig. 3D, i), giving a narrower
azimuthal distribution (Fig. 3D, ii; ∼10°, Fig. S5G). Despite its
reputation for being brittle, the PLLA does not fracture under the
tension at the OB during crimping; instead, the structure trans-
forms to one with orientation parallel to the OB and, thus, gains
tensile strength. The yielding and restructuring in the compact zone
near the inner bend (0–85 μm; Fig. 3B) preserve the integrity of the
rest of the material (100–160 μm; Fig. 3D) during crimping.
To mimic deployment of a scaffold in an artery, a crimped
scaffold is immersed for two minutes in phosphate-buffered saline
(PBS) at 37 °C and then radially expanded by inflation of a balloon.
The radial sequence of sections (Fig. 4B) shows notches at the inner
bend corresponding to the diamond-shaped void that forms upon
deployment (Fig. 1 F–G): the notch is deepest near the midplane
(D80 and D93; Fig. 4B). The birefringence in the deployed sections
is higher than that seen in the crimped sections (compare Fig. 2B to
Fig. 4B). Microdiffraction analysis was performed on section D40,
similar to the r position of section C45 above.
The 2D scattering patterns are remarkably similar at all positions
from IB to OB (Fig. 5 B–D, i). The intensity and azimuthal breadth
of the (110)/(200) diffraction peaks (Fig. 5 B–D, ii) and the relative
magnitude of the crystalline diffraction to the amorphous scat-
tering (Fig. 5 B–D, iii) hardly vary along the path from IB to OB.
In contrast to the dramatic variations in structure in the crimped
state (Figs. 2 and 3 and Fig. S5), the deployed state is remarkably
uniform (Figs. 4 and 5 and Fig. S6). During deployment, the IB is
placed under tension, and a diamond-shaped void is observed. In
the vicinity of the void, there is no evidence of fissures or yielding;
there are no craze fibrils crossing the diamond-shaped void, nor
any crazing near it. Deployment places the OB under compression,
yet again there are no indications of yielding; the material at the
OB retains the strong θ orientation (∼10°; Fig. S6E) that was seen
in the crimped state. Although the formation of diamond-shaped
voids might at first appear to be a defect in the scaffold, the
morphology in the deployed state suggests that the gentle sepa-
ration of the surfaces of the diamond-shaped void allows the
material to relax into a uniform, oriented structure, consistent
with mechanical integrity and radial strength in the bulk (group 3,
Fig. S2 E–H). Thus, the crazing and reorientation at the inner bend
produced by crimping permits the uniformity and integrity of the
deployed state, explaining the previously paradoxical observation
that scaffolds with a high incidence of diamond-shaped voids resist
fracture upon deployment (Fig. S2 G–H).
Conclusions
The structural integrity of BVSs is of paramount importance to
their clinical success (37). Scaffolds must not fracture even if
overdilated during implantation and must retain their strength for
6 mo (38) to support the occluded artery. The requirement of
lasting strength is the compelling advantage of pure PLLA relative
to more ductile PLLA blends or copolymers. The mechanical
strength of BVSs is governed by their semicrystalline microstruc-
ture, which is determined by the complex interplay of thermal and
strain histories imparted during tube expansion, crimping, and
deployment. Processing conditions for tube expansion must be
carefully selected because the resulting microstructure influences
the response of PLLA upon crimping and deployment.
The fine spatial resolution of microdiffraction data at the de-
formation regions of interest shows that the multiplicity of mor-
phologies created during crimping (Fig. 3) works in tandem to
enable deployment without failure. Looking back at the crimped
state (Fig. 2), it is noteworthy that the birefringence in the (θ, z)
Fig. 4. Variation in birefringence through the thickness of a deployed PLLA vascular scaffold. (A) Schematic of a U crest (Fig. 1G) indicating the OD surface, the
midplane (black dotted line), and the position of a particular section (black band). (B) Cropped polarized light micrographs of sequential 15-μm-thick microtomed
sections from the OD to the ID of a deployed U crest. Sections are labeled with D to denote “deployed” and the approximate distance in microns from the inner
diameter of the scaffold (i.e., D13 was closest to the ID of the scaffold, and D133 was closest to its OD). A bold rectangle indicates the section analyzed in Fig. 5.























plane was low at the IB, consistent with chains being oriented out of
plane (along r). In semicrystalline polymers, a graceful separation of
surfaces is possible when the chain axis is tangential to the surface
(no chains need to be extended or broken). Thus, the reorganization
of the semicrystalline structure during crimping sets the stage for
formation of the diamond-shaped voids (Fig. 1G) that permit de-
ployment with relatively little tensile stress at the IB. In turn, the low
tensile stress at the IB during deployment protects the OB from high
compressive stresses. The results presented in this report caution
against focusing solely on the tube expansion step in the design of
thinner scaffolds. Contrary to intuition, scaffolds gain strength from
the crimping process because it can impart a morphology that con-
fers ductility to a nominally brittle material.
Vascular scaffolds are designed to be as thin as possible to
minimize disruption of blood flow through coronary arteries. De-
spite the clinical success of 150-μm-thick scaffolds, clinicians seek
even thinner BVS to treat smaller and more complex arterial le-
sions. PLLA preforms can be expanded to a thickness comparable
to that of permanent stents (∼80 μm), but they must be strong
enough to resists vessel spasms (∼300 mm Hg) (12) to support the
occluded artery. Concerns regarding faster degradation of thinner
scaffolds are mitigated by the fact that there is negligible mass loss
at 12 mo for current BVSs—twice the time required for sup-
porting the artery (38). A thinner scaffold is expected to relieve the
compression of the inner bend during crimping and reduce the
out-of-plane strain; thus, the present results suggest that thinner
scaffolds will have proportionately smaller diamond-shaped voids.
To bring a thinner scaffold to the clinic, its hoop strength must
match that of current BVSs, requiring the material to have greater
strength; the present findings point to the crimping step as a key
process that can increase strength in thinner BVSs, extending their
benefits to a broader patient population.
Materials and Methods
Preparation of Vascular Scaffolds. The scaffolds used for this study were pro-
duced by Abbott Vascular through amultistep procedure: pure poly(L-lactide) with
a Tg between 60 and 65 °C was extruded into tubes; the extruded tubes were
expanded from an outer diameter of ∼1.5 mm to an outer diameter of 3.5 mm
and wall thickness of 150 μm using stretch blow molding; the scaffolds were
formed from the expanded tube by laser-cutting the desired pattern of axial struts
and azimuthal rings (Fig. S4A); and the scaffolds were coated with a 2- to 2.5-μm
layer of amorphous poly(D,L-lactide), similar to the clinical coating except for the
omission of the antiproliferative drug, crimped over a delivery balloon, and
sterilized with electron beam radiation. From the same batch of crimped scaffolds
used for this study, some of the scaffolds were deployed in vitro using balloon
inflation in a bath of saline at physiological temperature (37 °C). Thus, the crimped
and deployed scaffolds came from the same lot of PLLA and were processed
under the same specifications, on the same equipment, and by the same opera-
tors. The scaffolds were stored in a −80 °C freezer to preserve material properties
(i.e., prevent aging) and were taken out for sectioning. A detailed description of
the scaffold manufacturing process may be found in the patent literature (39, 40).
Microtomed Sections of Crimped and Deployed Subassemblies. Consecutive
sections in the (θ, z) plane, each ∼15 μm thick, were provided by Abbott Vascular.
The sections were obtained by carefully controlling the orientation of the scaf-
fold of interest (crimped or deployed) during embedding in a clear colorless
plastic methylmethacrylate-based embedding medium (Technovit 7100; Electron
Microscopy Sciences) using a 120-min cure at 25 °C. The size of the specimen
usually included two to three consecutive U crests (outlined in Fig. S4A), which
were oriented in the embedding material such that the U crests were in a plane
near the surface where the block face could be cut. The embedded sample was
glued to the microtome mounting post oriented with the r direction of the
Fig. 5. Structural characterization of a deployed U section (D40; bold rectangle in Fig. 4B). (A) Polarized light micrographs of D40 with increasing magnification
from A, i, to provide context relative to the IB and OB, to (A, iii) a composite image (vertical dotted lines mark transitions between images) that shows positions of
microdiffraction acquisitions (marked using the X-ray beam). Squares correspond to patterns shown in B–D. Microdiffraction data acquired (B) close to the IB,
(C) midway between the IB and OB, and (D) close to the OB: (i) X-ray microdiffraction patterns, (ii) azimuthal intensity distribution I(ϕ) at the (110)/(200) diffraction
(identified in D, i, azimuthal coordinates in B, i, averaged over q ∈ 1.08–1.24 Å−1), and (iii) radial intensity distribution I(q) (azimuthally averaged).
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sample parallel to the post axis. When placed in the microtome, the post was
rotated to orient the z axis of the sample parallel to the cutting direction.
Sections 15 μm thick were cut using a glass knife at −75 °C on a PowerTome
XL Ultra-Microtome. The block face was cut, and excess embedding material
was removed until the plane of the U crests was first exposed. Starting with
the first section that contained scaffold material, consecutive sections were
carefully retained and labeled in sequence order until the sections no longer
contained scaffold material. A representative section from a crimped sample
(Fig. S4B) shows consecutive U crests in embedding medium.
Scanning Electron Microscopy of As-Cut, Crimped, and Deployed Vascular
Scaffolds. The PLLA scaffolds were mounted on SEM sample stubs using carbon
tape and then sputter coated with gold to improve conductivity during image
acquisition. Images were acquired using a Zeiss 1550 VP Field Emission SEM at
California Institute of Technology and aHitachi S-4800 Field EmissionMicroscope
at Abbott Vascular.
X-Ray Microdiffraction Measurements on 15-μm-Thick Scaffold Sections. The
hard X-ray Scanning Microprobe (HXRSM) at beamline 2-ID-D of the APS at
the Argonne National Laboratory was used to acquire the microdiffraction data.
TheHXRSMcombinesmicrofocusing capabilitieswith X-ray sensitivity tomeasure
crystallographic strain and the ability to penetrate several microns through a
specimen. The HXRSM uses radiation from the high-brilliance source generated
by an electron beam of 7 GeV in the APS storage ring and a 3.3-cm-period
undulator. TheX-raymicroprobe radiationhas anenergy in the rangeof 6–20keV.
For the present experiments, X-rays with energy of 10.1 keV (λ = 1.227 Å) were
used. A combination of an Si(111) monochromator and a white beam slit located
43.5 m upstream of the zone plate can achieve a minimum spot size of 0.15 μm.
For our studies, a 0.2-μm beam spot size was used. Further details of the
beamline optics can be found in the literature (41). A Mar165 CCD area detector
at 2-ID-Dwas used to acquire 2D scattering patterns. The samples were mounted
on an aluminum holder. Using a CeO2 standard, the q range was calibrated, and
the sample-to-detector distance was measured to be 119.923 mm. A detailed
description of the X-ray analysis can be found in Figs. S7–S12.
Polarized Light Microscopy of Crimped and Deployed Scaffold Sections. Po-
larized light micrographs were acquired at 4×, 10×, or 32× magnification
through crossed linear polarizers using a Zeiss Universal microscope equip-
ped with a Canon EOS DS30 camera. Image composites at 32×magnification
were stitched together using Adobe Photoshop, Illustrator, and Microsoft
Powerpoint. Dotted white lines have been used to indicate the position
where two different images have been stitched together.
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